Benefits
Intestinal absorption of amino acids from whey protein
In a 30 person randomized crossover study, 50 mg twice daily for 4 weeks raised the blood level curve after a 25 g whey protein drink by 14% for valine and 8% for leucine versus placebo; isoleucine did not change significantly, and a single dose had no significant effect. Grip strength and muscle mass did not differ significantly from placebo. The maker donated the capsules, and no independent group has repeated it.
Arginine absorption, with other nutrients untested in people
In an acute crossover test, 50 mg the evening before and 50 mg with 5 g of L-arginine raised the arginine blood curve by 17% versus placebo, but only 24 of 30 completers were analysed after six were dropped for incomplete data or large individual differences. Claims for creatine, curcumin, vitamins and omega-3s rest on cell and animal work; no human study has measured them.
Gut barrier and microbiome markers
In a 3 month study of 8 adults with moderate ulcerative colitis (5 on AstraGin, 3 on placebo), 50 mg twice daily lowered fecal calprotectin and a gut permeability ratio versus the AstraGin group's own baseline, but these changes were not tested against placebo, and the microbe changes had no statistical test. In healthy adults, blood zonulin did not change significantly. This is too small to show a gut benefit.
Mechanism of action
Intestinal transporter upregulation and tight junction support
This is a proposed explanation drawn from intestinal cell culture and animal work, not something measured in the people who took AstraGin. The idea is that saponins in the extract raise the activity of nutrient transporters and tight junction proteins in the gut lining. No human study has measured transporter or tight junction expression after taking AstraGin, so treat this as a hypothesis behind the amino acid results rather than a demonstrated pathway.
Clinical trials
Randomized, double-blind, placebo-controlled crossover pilot (NCT06110260) of AstraGin (50 mg capsules of standardized Astragalus membranaceus and Panax notoginseng saponin extract) on whey protein amino acid absorption in 30 healthy adults, 10 in each of three age bands (18-25, 26-59, 60-80 years). Two phases: an acute test (one capsule the night before, one with 25 g whey protein) with 8 post-meal blood draws over 180 minutes, then 4 weeks of 50 mg twice daily with home-based resistance training, with a 4-week washout between arms. Funded by Chung Shan Medical University; the AstraGin and placebo capsules were donated by NuLiv Science, which sells the ingredient. No independent group has repeated it (Zhuang et al. 2026, Nutrients).
30 healthy adults, 10 aged 18-25, 10 aged 26-59 and 10 aged 60-80, each taking both AstraGin and placebo, with a 4-week washout between arms.
The acute test produced no significant change: valine AUC +6.67%, leucine +3.62%, isoleucine +0.15% versus placebo, and the paper states the differences were not significant. After 4 weeks the difference reached significance for two amino acids: valine AUC +14.07% and leucine +8.34% (both p < 0.05); isoleucine +6.33% did not. Arginine AUC rose 5.05%, with no significance test reported. Participants aged 60-80 showed a 12.74% higher total essential amino acid AUC. Grip strength improved in both arms over the 4 weeks (AstraGin +5.20%, placebo +2.44%), with only a main effect of time reported (p = 0.002) and no significant treatment effect; muscle mass changed +0.85% versus +0.68%. Blood zonulin fell 13.01% on AstraGin versus 0.90% on placebo, but this was not statistically significant (treatment p = 0.174, time p = 0.498, interaction p = 0.552). Creatinine, AST and ALT were unchanged; blood urea nitrogen rose significantly in both arms but stayed inside the normal range, and no adverse effects were reported. The authors call it a pilot study.
Randomized, double-blind, placebo-controlled parallel pilot in adults with moderate ulcerative colitis (Mayo score 4 to 9, fecal calprotectin above 200 mcg/g), given AstraGin 50 mg twice daily or a maltodextrin placebo for 3 months. Published in a journal not indexed in PubMed. Funded by Chung Shan Medical University; capsules provided by NuLiv Science. The healthy-adult trial measured zonulin only and did not sample the microbiome, so this pilot is the sole source of the microbiota figures quoted for AstraGin (Lin et al. 2023, J Biochem Biotech).
Adults with moderate ulcerative colitis, aged 25 to 70 (mean 43.4 years), 4 men and 5 women. Fourteen were screened, 9 were enrolled and 8 completed and were analysed: 5 on AstraGin and 3 on placebo.
Over 3 months, within the AstraGin arm fecal calprotectin fell 60.9% (p = 0.015), the lactulose to mannitol permeability ratio fell about 40% (p = 0.02) and myeloperoxidase activity fell 58% (p = 0.046); in the placebo arm calprotectin fell 10.9% and myeloperoxidase 7.0%, neither significant. Those p values compare each arm with its own baseline, not AstraGin with placebo. The one direct between-group comparison, L-arginine absorption, was 49.7% higher on AstraGin (p = 0.008). Faecalibacterium prausnitzii rose 420% and Bifidobacterium adolescentis rose 181% in the AstraGin group, reported as raw percentage changes with no significance test. Changes in IL-6, IL-17A, IL-1 beta, IL-10, microbiota alpha diversity and ghrelin were not significant, and the histological activity score fell 66.7% but did not reach significance (p = 0.078). With 5 people on AstraGin and 3 on placebo this is exploratory, and it was done in an inflammatory bowel condition rather than in healthy users.